Skip to main
CYRX
CYRX logo

CryoPort (CYRX) Stock Forecast & Price Target

CryoPort (CYRX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

CryoPort Inc. reported total revenue of $44 million, reflecting a 15% year-over-year growth on a constant currency basis, indicating consistent demand for its integrated temperature-controlled supply chain solutions within the life sciences industry. The company is witnessing a robust increase in gene therapy programs across various stages of development, particularly in oncology and rare diseases, which is expected to enhance its commercial revenue and clinical trial activities moving forward. As the market gains confidence in cell and gene therapies, CryoPort is positioned to continue benefiting from the upward trajectory of approved therapies and those in the development pipeline.

Bears say

The analysis of CryoPort's financial outlook indicates concerns rooted in declining funding for start-ups in the life sciences sector, which may adversely affect the company's growth trajectory. Although Life Sciences Services revenue showed a year-over-year increase, the slowdown in growth rate and an adjusted EBITDA margin that remains negative and below consensus expectations highlight potential profitability challenges. Furthermore, the anticipated decrease in demand for key products such as MVE freezers, along with a bearish outlook on earnings per share for 2026, bolsters the case for a cautious view on CryoPort's future performance.

CryoPort (CYRX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CryoPort (CYRX) Forecast

Analysts have given CryoPort (CYRX) a Buy based on their latest research and market trends.

According to 9 analysts, CryoPort (CYRX) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CryoPort (CYRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.